Aug 12, 2026 04:01PM
Aug 12, 2026 04:01PM
Jun 8, 2026 08:06AM
Jun 8, 2026 08:05AM
May 14, 2026 04:01PM
Mar 30, 2026 04:01PM
Mar 9, 2026 08:05AM Sangamo Therapeutics Advances Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease
Feb 3, 2026 04:07PM
Feb 3, 2026 04:05PM
Dec 18, 2025 08:05AM
Dec 18, 2025 08:05AM
Dec 2, 2025 08:05AM
Dec 2, 2025 08:05AM
Nov 21, 2025 08:05AM Sangamo gets FDA nod for rolling BLA submission of Fabry disease therapy
Nov 21, 2025 08:05AM
Nov 7, 2025 03:51AM
Nov 6, 2025 08:01AM
Sep 5, 2025 06:47AM
Sep 4, 2025 08:05AM
Sep 4, 2025 08:05AM
Aug 7, 2025 04:01PM Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2025 Financial Results
Jun 24, 2025 08:05AM
Jun 24, 2025 08:05AM
May 12, 2025 06:26PM
May 6, 2025 08:31AM
May 6, 2025 08:30AM
Mar 17, 2025 04:01PM
Feb 6, 2025 08:06AM Sangamo Therapeutics (SGMO) Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile
Feb 6, 2025 08:05AM
Nov 19, 2024 04:15PM
Nov 19, 2024 04:15PM
Nov 12, 2024 04:01PM
Nov 5, 2024 06:43AM
Oct 23, 2024 07:58AM
Oct 22, 2024 08:05AM Sangamo Therapeutics (SGMO) Announces Alignment With FDA on Accelerated Approval Pathway for ST-920
Oct 22, 2024 08:05AM
Aug 6, 2024 04:01PM
Jul 24, 2024 06:57AM
Jul 24, 2024 06:55AM
May 9, 2024 04:01PM
Mar 13, 2024 08:05AM
Feb 12, 2024 08:05AM Sangamo Therapeutics (SGMO) Announces FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920
Feb 12, 2024 08:05AM
Feb 6, 2024 05:52AM
Feb 5, 2024 06:01PM
Nov 1, 2023 04:01PM
Aug 8, 2023 04:01PM
May 22, 2023 08:05AM
May 22, 2023 08:05AM Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for Isaralgagene Civaparvovec for the Treatment of Fabry Disease
Apr 27, 2023 05:17AM

329,894 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All